These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6381868)

  • 1. [Effect of prostacyclin (PGI2) on retinal arteries].
    Zygulska-Machowa H; Kostka-Trabkowa E; Nitoń A; Dembińska-Kieciowa A; Kedzior A; Basista M; Gryglewski RJ
    Klin Oczna; 1984 Apr; 86(4):149-51. PubMed ID: 6381868
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostacyclin in treatment of peripheral vascular disease of lower extremities (author's transl)].
    Szczeklik A; Głusko P; Gryglewski R; Szczeklik J; Kostka-Trabka E; Grodzińska L; Nizanowski R; Dembińska-Kieć A; Skawiński S; Bieroń K; Billewicz O; Telesz E
    Przegl Lek; 1980; 37(9):659-62. PubMed ID: 6106960
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prostacyclins and arteriosclerosis].
    Gryglewski RJ
    Pol Arch Med Wewn; 1979 Dec; 62(6):473-7. PubMed ID: 394124
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostacyclin and vascular disease.
    Gryglewski RJ; Szczeklik A; Zygulska-Mach H; Kostka-Trabka E
    Philos Trans R Soc Lond B Biol Sci; 1981 Aug; 294(1072):383-8. PubMed ID: 6117899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of peripheral arterial disease with prostacyclin. I. Effect of prostacyclin on the healing of ischemic ulcers of the lower extremities].
    Nizankowski R
    Kardiol Pol; 1986; 29(3):209-17. PubMed ID: 3534429
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.
    Szczeklik A; Nizankowski R; Skawinski S; Szczeklik J; Gluszko P; Gryglewski RJ
    Lancet; 1979 May; 1(8126):1111-4. PubMed ID: 86835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostacyclin in the therapy of peripheral arterial disease.
    Szczeklik A; Gryglewski RJ; Nizankowski R; Szczeklik J; Skawiński S; Głuszko P
    Adv Prostaglandin Thromboxane Res; 1980; 7():687-9. PubMed ID: 6989195
    [No Abstract]   [Full Text] [Related]  

  • 8. [Significance of prostaglandins in arterial thrombosis pathology: survey of an ongoing experience].
    Duvivier A; David JL
    Rev Med Liege; 1984 May; 39(9):354-61. PubMed ID: 6203155
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical studies on the vasodilating and anti-platelet effects of OP-41483, a prostacyclin derivative.
    Kusaba A; Shiroma H; Shrestha DR; Koja K; Kina M; Kuniyoshi Y; Iha K; Kinjo O; Akasaki M; Kugai T
    Jpn J Surg; 1991 Jan; 21(1):8-13. PubMed ID: 2041246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostacyclin analogues as antiatherosclerotic drugs.
    Orekhov AN; Tertov VV; Smirnov VN
    Lancet; 1983 Aug; 2(8348):521. PubMed ID: 6136682
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prostacyclin (PGX, PGI2)-vascular anti-aggregation hormone regulating hemostasis].
    Feldman R
    Pol Arch Med Wewn; 1980 Jul; 64(1):57-67. PubMed ID: 6999470
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease.
    Bieroń K; Grodzińska L; Kostka-Trabka E; Gryglewski RJ
    Wien Klin Wochenschr; 1993; 105(1):7-11. PubMed ID: 8438599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostacyclin and atherosclerosis.
    Szczeklik A
    Triangle; 1980; 19(2):61-7. PubMed ID: 7003851
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue.
    Kaliman J; Fitscha P; Barth H; Sinzinger H
    Prog Clin Biol Res; 1987; 242():469-77. PubMed ID: 3313421
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of Sadamin on some blood clotting parameters and fibrinolysis in patients with obliterative arteriosclerosis of lower limb arteries].
    Kiersnowska B; Bielawiec M; Lukjan H; Korfel B; Rogowski F; Dowzyk W
    Pol Tyg Lek; 1973 Mar; 28(11):400-3. PubMed ID: 4694796
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostacyclin therapy in peripheral arterial disease.
    Szczeklik A; Gryglewski RJ; Nizankowski R; Skawiński S; Głuszko P; Korbut R
    Thromb Res; 1980 Jul 1-15; 19(1-2):191-9. PubMed ID: 6108623
    [No Abstract]   [Full Text] [Related]  

  • 17. [Possible aspects of the use of prostacyclin, prostaglandin E1 and their synthetic analogs in medical practice].
    Petrukhina GN; Makarov VA
    Eksp Klin Farmakol; 1995; 58(3):70-9. PubMed ID: 7663307
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibrinolytic activity and the effects of beta-pyridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans.
    Grodzińska L; Basista M; Kedzior A; Korbut R; Kostka-Trabka E; Gryglewski R
    Thromb Haemost; 1983 Dec; 50(4):797-9. PubMed ID: 6364447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostacyclin therapy of peripheral artery disease].
    Kusaba A
    Kokyu To Junkan; 1985 Jul; 33(7):871-6. PubMed ID: 3903902
    [No Abstract]   [Full Text] [Related]  

  • 20. A new prostacyclin analogue - an anticoagulant applicable to hemodialysis.
    Ota K; Kawaguchi H; Takahashi K; Ito K
    Trans Am Soc Artif Intern Organs; 1983; 29():419-24. PubMed ID: 6369729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.